Supriya Lifescience shares surge 17% on strong Q4 earnings; PAT rises 47% YoY

Supriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surging 50%. Robust demand across therapeutic segments, improved capacity utilisation, and traction in regulated markets supported growth. The stock remains in an uptrend despite overbought technical indicators.

More To Explore

India, Canada launch trade & investment forum

India and Canada have launched a trade and investment forum to boost commercial engagement and enhance connectivity. Commerce Minister Piyush Goyal’s visit also saw discussions

May 29, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003